ECSP056040A - 1,2, 4 SUSTITUIDO 1,2,3,4-TETRAHIDRO Y 1,2, DIHIDRO-QUINOLINA y 1,2,3,4-TETRADHIDRO-QUINOXALINA-DERIVADOS COMO INHIBIDORES CETP PARA EL TRATAMIENTO DE ATEROSCLEROSIS Y OBESIDAD - Google Patents

1,2, 4 SUSTITUIDO 1,2,3,4-TETRAHIDRO Y 1,2, DIHIDRO-QUINOLINA y 1,2,3,4-TETRADHIDRO-QUINOXALINA-DERIVADOS COMO INHIBIDORES CETP PARA EL TRATAMIENTO DE ATEROSCLEROSIS Y OBESIDAD

Info

Publication number
ECSP056040A
ECSP056040A EC2005006040A ECSP056040A ECSP056040A EC SP056040 A ECSP056040 A EC SP056040A EC 2005006040 A EC2005006040 A EC 2005006040A EC SP056040 A ECSP056040 A EC SP056040A EC SP056040 A ECSP056040 A EC SP056040A
Authority
EC
Ecuador
Prior art keywords
quinoline
tetradhidro
quinoxalina
aterosclerosis
tetrahydra
Prior art date
Application number
EC2005006040A
Other languages
English (en)
Inventor
George Chang
Mary Theresa Didiuk
Jari Ilmari Finneman
Ravi Shanker Garigipati
Ryan Michael Kelley
David Austen Perry
Roger Benjamin Ruggeri
Bruce Michael Bechle
Michael P Pollastri
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP056040A publication Critical patent/ECSP056040A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos de quinolina y quinoxalina, composiciones farmacéuticos que contienen tales compuestos y el uso de tales compuestos para aumentar ciertos niveles de lípidos en el plasma, incluyendo la lipoproteína de alta densidad del colesterol LDL y triglicéridos, y por consiguiente, para tratar enfermedades que se ven afectadas por los niveles bajos de colesterol HDL y/o niveles altos de colesterol-LDL y triglicéridos, tales como aterosclerosis y enfermedades cardiovasculares en ciertos mamíferos, incluyendo seres humanos.
EC2005006040A 2003-03-28 2005-09-26 1,2, 4 SUSTITUIDO 1,2,3,4-TETRAHIDRO Y 1,2, DIHIDRO-QUINOLINA y 1,2,3,4-TETRADHIDRO-QUINOXALINA-DERIVADOS COMO INHIBIDORES CETP PARA EL TRATAMIENTO DE ATEROSCLEROSIS Y OBESIDAD ECSP056040A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45827403P 2003-03-28 2003-03-28

Publications (1)

Publication Number Publication Date
ECSP056040A true ECSP056040A (es) 2006-01-27

Family

ID=33098266

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006040A ECSP056040A (es) 2003-03-28 2005-09-26 1,2, 4 SUSTITUIDO 1,2,3,4-TETRAHIDRO Y 1,2, DIHIDRO-QUINOLINA y 1,2,3,4-TETRADHIDRO-QUINOXALINA-DERIVADOS COMO INHIBIDORES CETP PARA EL TRATAMIENTO DE ATEROSCLEROSIS Y OBESIDAD

Country Status (25)

Country Link
EP (1) EP1622872A1 (es)
JP (1) JP2006521344A (es)
KR (1) KR100729883B1 (es)
CN (1) CN1795177A (es)
AR (1) AR044507A1 (es)
AU (1) AU2004224082A1 (es)
BR (1) BRPI0408897A (es)
CA (1) CA2520405A1 (es)
CL (1) CL2004000639A1 (es)
EA (1) EA200501376A1 (es)
EC (1) ECSP056040A (es)
GT (1) GT200400050A (es)
HR (1) HRP20050859A2 (es)
MA (1) MA27828A1 (es)
MX (1) MXPA05010456A (es)
NL (1) NL1025839C2 (es)
NO (1) NO20054989L (es)
OA (1) OA13153A (es)
PA (1) PA8598901A1 (es)
PE (1) PE20050389A1 (es)
TN (1) TNSN05243A1 (es)
TW (1) TWI285641B (es)
UY (1) UY28243A1 (es)
WO (1) WO2004085401A1 (es)
ZA (1) ZA200507819B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101078098B1 (ko) 2003-01-14 2011-10-28 아레나 파마슈티칼스, 인크. 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
EP3345895B1 (en) 2003-04-11 2019-12-04 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
AR045697A1 (es) 2003-07-14 2005-11-09 Arena Pharm Inc Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
AU2006216713A1 (en) * 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7888376B2 (en) * 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
US7745477B2 (en) * 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
AU2007247385B2 (en) 2006-05-10 2011-07-14 Novartis Ag Bicyclic derivatives as CETP inhibitors
JP4108729B2 (ja) * 2006-05-26 2008-06-25 日本たばこ産業株式会社 窒素含有縮合環化合物含有医薬組成物
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
KR20090078352A (ko) * 2006-11-15 2009-07-17 노파르티스 아게 유기 화합물
JP4846769B2 (ja) * 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
CA2696609C (en) 2007-08-27 2017-09-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
MX2011003951A (es) * 2008-10-29 2011-05-03 Hoffmann La Roche Nuevos derivados de fenilamida o de piridilamida y su uso como agonistas de receptor acoplado a proteina g (gpbar1).
US8420647B2 (en) * 2010-01-21 2013-04-16 Hoffmann-La Roche Inc. 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9422281B2 (en) * 2013-11-18 2016-08-23 Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors
WO2015074064A2 (en) 2013-11-18 2015-05-21 Bair Kenneth W Tetrahydroquinoline compositions as bet bromodomain inhibitors
JP6946001B2 (ja) 2014-03-06 2021-10-06 ピーティーシー セラピューティクス， インコーポレイテッド 薬学的組成物、および１，２，４−オキサジアゾール安息香酸の塩
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
HK1251965A1 (zh) 2015-10-30 2019-05-10 Ptc医疗公司 用於治疗癫痫的方法
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN110452183B (zh) * 2019-09-04 2023-03-14 中国科学院上海有机化学研究所 一种手性杂环化合物的制备方法
CN111440162A (zh) * 2020-04-01 2020-07-24 邱曲真 噻唑二氢萘类衍生物及其在代谢性疾病中的应用
CN114656406B (zh) * 2022-01-25 2023-09-05 阿里生物新材料（常州）有限公司 一种2-氟代嘧啶-4-羧酸的合成方法
CN115894358B (zh) 2022-10-25 2025-05-27 广东省农业科学院蚕业与农产品加工研究所 一种具有脂肪酶抑制活性的米糠生物碱、药物组合物及其制备方法和应用
WO2025111184A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE351464C (de) * 1917-12-18 1922-04-07 Chemische Werke Grenzach Aktie Verfahren zur Darstellung von Derivaten einer hydrierten 2-Phenylchinolin-4-carbonsaeure
CZ176197A3 (cs) * 1994-12-22 1998-09-16 Ligand Pharmaceuticals Incorporated Modulátory steroidových receptorů a způsoby jejich přípravy a použití
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
EP1051413B1 (en) * 1998-01-26 2003-06-04 SmithKline Beecham plc Quinoline derivatives as antibacterials
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5271716A1 (es) * 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida

Also Published As

Publication number Publication date
EP1622872A1 (en) 2006-02-08
NO20054989D0 (no) 2005-10-26
TW200508222A (en) 2005-03-01
BRPI0408897A (pt) 2006-04-18
PE20050389A1 (es) 2005-05-30
JP2006521344A (ja) 2006-09-21
NL1025839C2 (nl) 2006-09-06
WO2004085401A1 (en) 2004-10-07
OA13153A (en) 2006-12-13
TNSN05243A1 (fr) 2007-06-11
PA8598901A1 (es) 2004-11-26
AR044507A1 (es) 2005-09-14
AU2004224082A1 (en) 2004-10-07
NO20054989L (no) 2005-12-16
KR20050115938A (ko) 2005-12-08
CL2004000639A1 (es) 2005-02-04
HRP20050859A2 (en) 2006-02-28
TWI285641B (en) 2007-08-21
GT200400050A (es) 2005-03-02
EA200501376A1 (ru) 2006-04-28
KR100729883B1 (ko) 2007-06-18
MXPA05010456A (es) 2006-03-21
CA2520405A1 (en) 2004-10-07
ZA200507819B (en) 2007-04-25
MA27828A1 (fr) 2006-04-03
UY28243A1 (es) 2004-11-08
NL1025839A1 (nl) 2004-09-30
CN1795177A (zh) 2006-06-28
WO2004085401A8 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
ECSP056040A (es) 1,2, 4 SUSTITUIDO 1,2,3,4-TETRAHIDRO Y 1,2, DIHIDRO-QUINOLINA y 1,2,3,4-TETRADHIDRO-QUINOXALINA-DERIVADOS COMO INHIBIDORES CETP PARA EL TRATAMIENTO DE ATEROSCLEROSIS Y OBESIDAD
CR9089A (es) Compuestos y derivados de dibencil amina
PA8481201A1 (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino
UY30197A1 (es) Compuestos y derivados de dibencilamina
CR6310A (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas
CL2012001124A1 (es) Composición farmacéutica que comprende un extracto terapéutico concentrado, que comprende fosfolípidos en concentración de 60 a 99% y uso para tratar enfermedades cardiovasculares, reducir niveles de triglicérido, reducir colesterol ldl y aumentar colesterol hdl.
UY28097A1 (es) Activadores de ppar
SV2003000886A (es) Agonistas de ppar ref. pc11023aado/bb
CR9012A (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina
BRPI0410479A (pt) derivados de tetraidroisoquinolina como ativadores do ppar-(alfa)
EA200801815A1 (ru) Дибензиламиносоединения и производные
UY29124A1 (es) Compuestos de quinolina
BRPI0607839A2 (pt) compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)-amino]-propan- 2-ol substituìdos
DOP2004000863A (es) Compuestos de quinolina y quinoxalina
DOP2005000179A (es) Compuesto de quinolina
DOP2003000762A (es) Activadores de ppar
DOP2002000327A (es) Agonistas de ppar
UY29123A1 (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina
DOP2005000238A (es) Compuestos y derivados de dibencil amina
ECSP088730A (es) Derivados de dibencilamina como inhibidores de cetp
UY27168A1 (es) Agonistas de ppar
DOP2005000182A (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3-tetrahidroquinolina
PA8589501A1 (es) Activadores de ppar
CU20080164A7 (es) Compuestos y derivados de dibencilamina
SV2006002314A (es) Compuestos y derivados de dibencil amina ref. no. pc32592a